Dr. Gray comes to Enosi with more than 40 years of experience in the biotech, biochemistry, and molecular biology sectors. During his time in the field, he's developed over 40 U.S. patents for more than 20 different technologies. His experience and dedication to developing new ways to improve people's health made him the perfect candidate to advance Enosi's next generation of autoimmune, cancer and acute inflammation therapies that induce disease regression, and prevent relapse while dramatically reducing patient side effects.
Dr. Gray's long list of accomplishments includes the first cloning and characterization of the Hepatitis B viral surface antigen. This work led to the development of the HBV vaccine that saves approximately two million lives a year. Dr. Gray's dedication to drug discovery and saving lives will help provide leadership, direction, and vision to Enosi's rapidly growing organization.
Before being named Enosi Life Sciences CEO, Dr. Gray served as CEO for Pascal Biosciences (2015-2021) and was CEO of Nura, Inc. (2003-2006). Dr. Gray has had close relationships with Enosi founders, since he began his career in biotechnology in 1980 at Genentech as a coworker of Dr. Shepard, and he was a scientist in Dr. Feldmann's lab from 1989-1990. Dr. Gray has also received awards and honors throughout his career including a Distinguished Alumni Fellows Award from his alma mater, the University of Oregon. He holds a Ph.D. in Chemistry from the University of Colorado, Boulder, CO.
Current role